HW
ENTA icon

Hancock Whitney’s Enanta Pharmaceuticals ENTA Stock Holding History

Hancock Whitney’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,761
Closed -$284K – 833
2021
Q1 		$284K Buy
+5,761
New +$287K 0.01% 658
2020
Q4 		– Sell
-4,979
Closed -$228K – 808
2020
Q3 		$228K Sell
4,979
-25
-0.5% -$1.21K 0.01% 690
2020
Q2 		$251K Buy
+5,004
New +$259K 0.01% 664

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Hancock Whitney's ENTA Position: Q2 2021 in Review

Hancock Whitney sold out of Enanta Pharmaceuticals (ENTA) in Q2 2021, closing a stake of 5,761 shares — an estimated $284K sold.

Hancock Whitney first reported a position in ENTA in Q2 2020 and held it in 3 quarters. The position peaked at $284K in Q1 2021. 151 funds tracked by Wall St. Rank hold ENTA as of Q2 2021.

  • Hancock Whitney reported no remaining Enanta Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Hancock Whitney sold 5,761 Enanta Pharmaceuticals shares in Q2 2021, an estimated $284K.
  • Hancock Whitney first reported a position in Enanta Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • Hancock Whitney's Enanta Pharmaceuticals position peaked at $284K in Q1 2021.
  • 151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2021.

Based on Hancock Whitney's 13F filing for Q2 2021, filed 9 Aug 2021.